Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis
<strong>Background</strong> Tamoxifen was recommended by NICE in 2013 for chemoprevention of breast cancer, but a recent survey suggested only a quarter of GPs are aware of this. We set out to measure the uptake of tamoxifen, and the alternative raloxifene, in national prescribing data s...
| Main Authors: | , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Springer Nature
2018
|